​

Avalo Therapeutics (AVTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

AVTX Stock Forecast

Avalo Therapeutics (AVTX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $35.00, with a high of $35.00 and a low of $35.00. This represents a 317.66% increase from the last price of $8.38.

- $7 $14 $21 $28 $35 High: $35 Avg: $35 Low: $35 Last Closed Price: $8.38

AVTX Stock Rating

Avalo Therapeutics stock's rating consensus is Hold, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (40.00%), 3 Hold (60.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 5 0 3 2 Strong Sell Sell Hold Buy Strong Buy

AVTX Price Target Upside V Benchmarks

TypeNameUpside
StockAvalo Therapeutics317.66%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$35.00
Last Closing Price$8.38$8.38$8.38
Upside/Downside--317.66%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25-21--3
Jan, 25-21--3
Dec, 24-21--3
Nov, 24111--3
Oct, 24111--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 16, 2024Leland GershellOppenheimer$35.00$15.24129.66%317.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 19, 2024BTIGBuyinitialise
Oct 24, 2024H.C. WainwrightNeutralinitialise
Aug 15, 2024OppenheimerOutperformOutperformhold
Apr 16, 2024OppenheimerOutperformupgrade
Jun 27, 2023StephensEqual-WeightEqual-Weighthold
Feb 08, 2023JefferiesUnderperformdowngrade

Financial Forecast

EPS Forecast

$-3K $-2K $-2K $-1K $-500 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-10.52$-9.71$-4.43$-114.00-----
Avg Forecast$-2.28K$-2.26K$-698.40$-96.00$-25.79$-5.31$-4.30$-4.48$-3.08
High Forecast$-2.28K$-2.26K$-711.78$-96.00$-49.35$-5.51$-6.35$-4.48$-3.08
Low Forecast$-2.28K$-2.26K$-691.71$-96.00$-2.22$-5.10$-1.66$-4.48$-3.08
Surprise %-99.54%-99.57%-99.37%18.75%-----

Revenue Forecast

$0 $5M $10M $15M $20M $25M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.70M$5.40M$18.05M$1.41M-----
Avg Forecast$5.20M$6.08M$20.80M$1.70M$150.00K$1.00M$1.00M$1.00M$1.71M
High Forecast$5.20M$6.08M$20.64M$1.70M$130.43K$1.00M$1.00M$1.00M$1.71M
Low Forecast$5.20M$6.08M$21.10M$1.70M$163.04K$1.00M$1.00M$1.00M$1.71M
Surprise %28.83%-11.28%-13.20%-17.18%-----

Net Income Forecast

$-650M $-520M $-390M $-260M $-130M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-64.38M$-84.35M$-41.66M$-31.54M-----
Avg Forecast$-631.89M$-627.09M$-193.97M$-26.66M$-8.13M$-1.47M$-1.11M$-1.24M$-854.01K
High Forecast$-631.89M$-627.09M$-197.68M$-26.66M$-13.71M$-1.53M$-1.76M$-1.24M$-854.01K
Low Forecast$-631.89M$-627.09M$-192.11M$-26.66M$-615.98K$-1.42M$-461.46K$-1.24M$-854.01K
Surprise %-89.81%-86.55%-78.52%18.31%-----

AVTX Forecast FAQ

Is Avalo Therapeutics stock a buy?

Avalo Therapeutics stock has a consensus rating of Hold, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Avalo Therapeutics is a neutral investment for most analysts.

What is Avalo Therapeutics's price target?

Avalo Therapeutics's price target, set by 5 Wall Street analysts, averages $35 over the next 12 months. The price target range spans from $35 at the low end to $35 at the high end, suggesting a potential 317.66% change from the previous closing price of $8.38.

How does Avalo Therapeutics stock forecast compare to its benchmarks?

Avalo Therapeutics's stock forecast shows a 317.66% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for Avalo Therapeutics over the past three months?

  • February 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Avalo Therapeutics’s EPS forecast?

Avalo Therapeutics's average annual EPS forecast for its fiscal year ending in December is $-25.79 for 2024, a -77.38% decrease from the reported $-114 in 2023. The prediction for 2025 is $-5.31, $-4.3 for 2026, $-4.48 for 2027, and $-3.08 for 2028.

What is Avalo Therapeutics’s revenue forecast?

Avalo Therapeutics's average annual revenue forecast for its fiscal year ending in December is $150K for 2024, a -89.35% decrease from the reported $1.41M in 2023. The forecast for 2025 is $1M, $1M for 2026, $1M for 2027, and $1.71M for 2028.

What is Avalo Therapeutics’s net income forecast?

For its fiscal year ending in December, Avalo Therapeutics's average annual net income forecast is $-8.135M for 2024, reflecting a -74.21% decrease from the reported $-31.544M in 2023. The projection for 2025 is $-1.474M, $-1.113M for 2026, $-1.244M for 2027, and $-854K for 2028.